CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

rintatolimod

Nucleic acidexperimentalCOVID-19

Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). There is some evidence it may improve some ME/CFS symptoms. — Wikipedia

Clinical trial activity

27 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
13
Phase 2
22
Phase 3
2
Phase 4
0

Earliest trial started Mar 1, 1997 (NCT00215813)

Timeline

1990s

  1. Jan 1, 1997

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2001

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ampligen
  • ampligen
  • ampligen
  • mismatched double-stranded rna
  • poly(inosinic acid) poly(cytidylic(12), uridylic)acid
  • poly i:poly c12u
  • poly i:poly c12u
  • poly(i)-poly(c12u)
  • poly(i).poly(c12,u)
  • (ri(n).r(c(12)u)n)
  • rintatolimod
  • rintatolimod
  • rintatolimod
  • rintatolimod

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05927142Phase 1/Phase 2 (Phase 2)Dec 31, 2023Erasmus University Rotterdam
NCT05756166Phase 1/Phase 2 (Phase 2)Dec 30, 2023National Cancer Institute (NCI), State University of New York, Buffalo
NCT05592418Phase 2Mar 31, 2023Amarex Clinical Research, Hemispherx Biopharma
NCT05494697Phase 2Sep 30, 2022Amarex Clinical Research, Hemispherx Biopharma
NCT04348747Phase 2Jun 1, 2020Department of Defense, State University of New York, Buffalo
NCT04379518Phase 1/Phase 2 (Phase 2)May 30, 2020National Cancer Institute (NCI), State University of New York, Buffalo
NCT04119830Phase 2Oct 30, 2019Merck, State University of New York, Buffalo
NCT04093323Phase 2Oct 1, 2019National Cancer Institute (NCI), State University of New York, Buffalo
NCT04081389Phase 1/Phase 2 (Phase 2)Sep 3, 2019State University of New York, Buffalo
NCT03899987Phase 2Aug 1, 2019Hemispherx Biopharma, State University of New York, Buffalo
NCT03734692Phase 1/Phase 2 (Phase 2)Jan 28, 2019Hemispherx Biopharma, Merck, University of Pittsburgh
NCT03599453Phase 2Oct 31, 2018State University of New York, Buffalo
NCT03403634Early Phase 1 (Phase 1)Mar 27, 2018National Cancer Institute (NCI), State University of New York, Buffalo
NCT02615574Phase 2Mar 1, 2016University of Pittsburgh
NCT02151448Phase 1/Phase 2 (Phase 2)Jul 1, 2014National Cancer Institute (NCI), University of Pittsburgh
NCT01545141Phase 1/Phase 2 (Phase 2)Oct 1, 2012Hemispherx Biopharma, University of Pittsburgh
NCT01591473Phase 1/Phase 2 (Phase 2)Apr 1, 2012Hemispherx Biopharma
NCT01355393Phase 1/Phase 2 (Phase 2)Jul 1, 2011National Cancer Institute (NCI), University of Washington
NCT01312389Phase 1/Phase 2 (Phase 2)Mar 1, 2011University of Pennsylvania
NCT00035893Phase 2May 1, 2001Hemispherx Biopharma
Showing 20 of 27 trials
Page 1 / 2

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hemispherx BiopharmaFor profit11831997
State University of New York, BuffaloAcademic/Hospital9922018
National Cancer Institute (NCI)Government6022011
University of PittsburghAcademic/Hospital4412012
National Institute of Allergy and Infectious Diseases (NIAID)Government3321999
Amarex Clinical ResearchFor profit2012022
MerckFor profit2012019
Bateman Horne CenterAcademic/Hospital1011997
Department of DefenseGovernment1012020
Erasmus University RotterdamAcademic/Hospital1112023
Hunter-Hopkins Center, P.A.Academic/Hospital1011997
University of PennsylvaniaAcademic/Hospital1112011
University of WashingtonAcademic/Hospital1112011
13 organizations
Page 1 / 1